ArticleOncotarget2016
Assessment of combined expression of B7-H3 and B7-H4 as prognostic marker in esophageal cancer patients.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Review
- B7H4 Role in Solid Cancers: A Review of the Literature.Cancers · 2024Review
- Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer.Frontiers in immunology · 2022Article
- B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors.World journal of gastrointestinal oncology · 2021Review
- B7-H3 targeted antibody-based immunotherapy of malignant diseases.Expert opinion on biological therapy · 2021Article
- Expression of a novel immune checkpoint B7-H6 ligand in human small cell lung cancer.Annals of translational medicine · 2020Article
- High expression of B7‑H2 or B7‑H3 is associated with poor prognosis in hepatocellular carcinoma.Molecular medicine reports · 2019Article
- Comprehensive molecular profiling of the B7 family in gastrointestinal cancer.Cell proliferation · 2018Article
- B7-Homolog 4 Promotes Epithelial-Mesenchymal Transition and Invasion of Bladder Cancer Cells via Activation of Nuclear Factor-κB.Oncology research · 2018Article
- Roles of B7-H3 in Cervical Cancer and Its Prognostic Value.Journal of Cancer · 2018Article
- Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma.Cell death & disease · 2017Article
- B7-H4 promotes tumor growth and metastatic progression in lung cancer by impacting cell proliferation and survival.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The co-stimulatory ligands of B7-family have been confirmed to play an important role in negatively regulating the T-cell mediated anti-tumor immunity. In addition, these inhibitory molecules are also aberrantly expressed on various human cancers tissues, and significantly associated with cancer progression and patients' poor prognoses. We have previously reported that B7-H3 and B7-H4 ligands are highly expressed in human esophageal cancer tissues. Herein, we tried to further analyze the value of their combined expression on prognostic prediction for esophageal cancer patients. We found that the combined expression of both B7-H3 and B7-H4 could be used as a valuable risk factor for predicting the prognosis of esophageal cancer patients (P=0.003). Moreover the status of these patients with high expression of both B7-H3 and B7-H4, was positively and significantly associated with the tumor invasion depth (P=0.0414) and TNM stage (P=0.0414). The Cox multivariate proportional hazards regression analysis revealed that the tumor size (P=0.007), the TNM stage (P=0.024) and the status of both B7-H3 and B7-H4 high expression (P=0.011), could be used as an independent risk factor for predicting patients' postoperative prognosis, respectively. In conclusion, our data indicated that the combined application of B7-H3 and B7-H4 expression can be effectively used as a prognostic marker in esophageal cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.